Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: A population-based case-control study

International Journal of Clinical Practice

Volumn 68, Issue 10, 2014, Pages 1193-1199

  Chung, W S ^a,b   Chen, Y F ^b,c   Hsu, J C ^d   Yang, W T ^a   Chen, S C ^e   Chiang, J Y ^f,g  

^a TAICHUNG HOSPITAL   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d TAO YUAN GENERAL HOSPITAL   (Taiwan)

^e Taichung Hospital   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG USE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LOW DRUG DOSE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POPULATION BASED CASE CONTROL STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; CASE CONTROL STUDY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; RISK FACTOR; TAIWAN; TUBERCULOSIS, PULMONARY; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TUBERCULOSIS, PULMONARY;

EID: 84908230638     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12459     Document Type: Article

References (34)

1. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-78.
2. Man SF, Sin DD,. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit? Drugs 2005; 65: 579-91.
3. Gartlehner G, Hansen RA, Carson SS, Lohr KN,. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006; 4: 253-62.
4. CDC. Taiwan Tuberculosis Control Report, 2012. In:, Chang FY, Shi WY, Chou JH, Chen YW, Chuang JH, Chen CH, Yang SL, Lo HY, eds. Centers for Disease Control. R.O.C. (Taiwan): Department of Health, 2012.
5. CDC. Reported Tuberculosis in the United States, 2012. In: U.S. Department of Health and Human Services. Atlanta, GA: CDC, 2013.
6. Canada PHAo. Tuberculosis in Canada 2010. In: Centre for Communicable Diseases and Infection Control. Ottawa: Public Health Agency of Canada, 2012.
7. Jeon CY, Murray MB,. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008; 5: e152.
8. Kamboj M, Sepkowitz KA,. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006; 42: 1592-5.
9. Thulstrup AM, Molle I, Svendsen N, Sorensen HT,. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study. Epidemiol Infect 2000; 124: 221-5.
10. Baijal R, Praveenkumar HR, Amarapurkar DN, Nagaraj K, Jain M,. Prevalence of tuberculosis in patients with cirrhosis of liver in western India. Trop Doct 2010; 40: 163-4.
11. Hu HY, Wu CY, Huang N, Chou YJ, Chang YC, Chu D,. Increased risk of tuberculosis in patients with end-stage renal disease: a population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Epidemiol Infect 2014; 142: 191-9.
12. Lin CY, Chen TC, Lu PL, et al. Effects of gender and age on development of concurrent extrapulmonary tuberculosis in patients with pulmonary tuberculosis: a population based study. PLoS ONE 2013; 8: e63936.
13. Slama K, Chiang CY, Enarson DA, et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis 2007; 11: 1049-61.
14. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21.
15. Chang KC, Leung CC, Tam CM,. Tuberculosis risk factors in a silicotic cohort in Hong Kong. Int J Tuberc Lung Dis 2001; 5: 177-84.
16. Jick SS, Lieberman ES, Rahman MU, Choi HK,. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55: 19-26.
17. Bellofiore B, Matarese A, Balato N, et al. Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers. J Rheumatol Suppl 2009; 83: 76-7.
18. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998; 16: 9-13.
19. Brassard P, Kezouh A, Suissa S,. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 717-22.
20. Bahceciler NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB, Basaran MM,. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. Pediatr Infect Dis J 2000; 19: 215-8.
21. Brassard P, Suissa S, Kezouh A, Ernst P,. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011; 183: 675-8.
22. Cheng TM,. Taiwan's National Health Insurance system: high value for the dollar. In:, Okma KGH, Crivelli L, eds. Six Countries, Six Reform Models: The Health Reform Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. Hackensack, NJ: World Scientific, 2009: 71-204.
23. Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 2013; (in press). doi: 10.1136/annrheumdis-2013-203380.
24. Chung WS, Lin CL, Ho FM, et al. Asthma increases pulmonary thromboembolism risk: a nationwide population cohort study. Eur Respir J 2014; 43: 801-7.
25. Shu CC, Wu HD, Yu MC, et al. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore) 2010; 89: 53-61.
26. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA) and the sections of this statement. Am J Respir Crit Care Med 1999; 2000 (161): S221-47.
27. Lipworth BJ,. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-55.
28. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ,. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013; 68: 1105-13.
29. Louis R, Schleich F, Barnes PJ,. Corticosteroids: still at the frontline in asthma treatment? Clin Chest Med 2012; 68: 1105-13.
30. Chung WS, Chang RE, Guo HR,. Variations of care quality for infectious pulmonary tuberculosis in Taiwan: a population based cohort study. BMC Public Health 2007; 7: 107.
31. Panjabi R, Comstock GW, Golub JE,. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007; 11: 828-37.
32. Chiang CY, Riley LW,. Exogenous reinfection in tuberculosis. Lancet Infect Dis 2005; 5: 629-36.
33. Barnes PF, Cave MD,. Molecular epidemiology of tuberculosis. N Engl J Med 2003; 349: 1149-56.
34. Ricks PM, Cain KP, Oeltmann JE, Kammerer JS, Moonan PK,. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005-2009. PLoS ONE 2011; 6: e27405.